SP-X® Imaging and Analysis System

SP-X Imaging and Analysis System: Next-Generation Simoa Planar Array Technology for Ultra-Sensitive Multiplex Biomarker Detection

The SP-X Imaging and Analysis System represents a revolutionary advancement in ultra-sensitive multiplex biomarker quantification, combining next-generation Simoa Planar Array technology with high-resolution imaging and AI-powered analytical algorithms. This complete benchtop platform enables true multiplex detection at both acute and baseline levels, offering unprecedented sensitivity for circulating biomarker measurement at the earliest stages of disease progression, even at healthy baseline levels.

Built on proprietary planar array technology, the SP-X system replaces traditional bead-based Simoa platforms with glass slide-based planar arrays, enabling simultaneous detection of up to 10 biomarkers with sub-picomolar sensitivity. The platform leverages high-precision nanofluidic antibody deposition technology to create capture antibody arrays in a circular pattern within microwells, with over 200,000 reaction sites per plate. This innovative design, combined with proprietary surface chemistry that creates a unique "vortex effect," delivers 1000-fold concentration of assay signal and reduction in non-specific background interference.

The SP-X system excels in multiple therapeutic areas including oncology, immuno-oncology, neurodegenerative disease research, cardiovascular studies, inflammation research, and drug development. For oncology and immuno-oncology applications, the platform enables sensitive detection of circulating cytokines and immune-related biomarkers to monitor immunotherapy response. In neurodegenerative disease research, it provides ultra-sensitive quantification of neurological proteins including Tau, neurofilament light chain, and GFAP. The platform's multiplex capabilities make it ideal for inflammation research, enabling comprehensive profiling of cytokine networks and immune regulation mechanisms.

Key technical specifications include exceptional optics with a high-resolution camera and custom lens for optimal light collection, achieving imaging time of less than 2.5 minutes per plate. The system incorporates proprietary image acquisition algorithms and machine learning to maximize dynamic range and signal-to-noise ratio. With a compact footprint requiring only 11 inches of space and a built-in touchscreen tablet interface, the SP-X offers convenience and ease of use. The platform requires minimal sample volume—just 12.5 µL of human serum or plasma per replicate—making it ideal for precious clinical samples.

Clinical validation studies have demonstrated impressive analytical performance. A 10-plex human cytokine assay targeting IFNγ, IL-1β, IL-4, IL-5, IL-6, IL-8, IL-10, IL-12p70, IL-22, and TNFα achieved sub-picomolar limits of detection for all analytes, with lower limits of quantification ranging from 0.1 to 1.4 pg/mL. In normal human serum and plasma, more than 80% of healthy samples were quantifiable above the LLOQ for most analytes, demonstrating superior sensitivity compared to traditional ELISA and existing multiplex immunoassay technologies.

The SP-X platform supports both ready-to-use Simoa Planar Kits and custom Homebrew assay development, providing researchers with flexibility to explore novel biomarkers or optimize existing assays for specific research needs. The universal planar assay format has been validated for minimal cross-reactivity and matrix interference, ensuring reliable performance across diverse applications. Data can be viewed and analyzed directly on the system or exported to commonly used software packages or laboratory information management systems for advanced statistical analysis and data integration.

For translational medicine and precision health applications, the SP-X system accelerates biomarker discovery and validation by enabling measurement of protein concentrations previously undetectable with conventional methods. This capability supports earlier disease detection, better prognoses, and enhanced treatment monitoring strategies. In drug development, the platform facilitates target engagement assessment, pharmacodynamic biomarker measurement, and dose-response evaluation in preclinical and clinical studies.

The SP-X Imaging and Analysis System represents a paradigm shift in biomarker research, combining Simoa ultra-sensitivity with powerful multiplexing scale and flexibility. Its low maintenance design requires no calibration, allowing researchers to focus on experimental design and data analysis rather than instrument maintenance. This next-generation platform empowers oncology researchers, immunologists, neuroscientists, and drug developers to optimize workflows, accelerate research timelines, and ultimately bring new therapeutic discoveries to patients faster.